Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients
Salih Demirhan,Marc Foca,Flor M Munoz,Kristen G Valencia Deray,Claire E Bocchini,Tanvi S Sharma,Gilad Sherman,William Muller,Taylor Heald Sargent,Lara Danziger-Isakov,Samantha Blum,Juri Boguniewicz,Samantha Bacon,Tuhina Joseph,* Jodi Smith,Monica I Ardura,Gabriela M Maron,Yin Su,Jose Ferrolino,Betsy C Herold
DOI: https://doi.org/10.1093/jpids/piae093.072
2024-11-04
Journal of the Pediatric Infectious Diseases Society
Abstract:BackgroundValganciclovir (VGCV) prophylaxis against cytomegalovirus (CMV) infection and disease has provided an important advance in the management of pediatric solid organ transplantation (SOT) recipients over the past two decades. However, there remain significant questions regarding its relative safety and efficacy, optimal dosing strategies, and toxicities including neutropenia and lymphopenia. We performed a multi-center retrospective study of children post SOT who were to receive at least 3 months of valganciclovir. The primary outcomes were CMV DNAemia while receiving prophylaxis (breakthrough) and post-prophylaxis CMV DNAemia within the first year.MethodsThe study population included patients ≤ 20 years of age at the time of their first transplant between January 2016 and December 2019 from 8 US centers in PIDTRAN Network. Data for each patient was extracted from the electronic medical record and entered into a REDcap database hosted by St. Jude Children's Research Hospital. Variables analyzed included demographics, donor/recipient CMV serostatus, immunosuppression, trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis use, rejection, other viral or bacterial infections and one-year survival. Statistics were performed using STATA software for univariate and multivariate models; p-value< 0.05 was considered statistically significant.Results749 pediatric SOT patients were enrolled over the 3-year study period. Breakthrough DNAemia occurred in 85 (11.4%) patients and post-prophylaxis CMV DNAemia was documented in an additional 46 (6.9%) patients. CMV disease occurred in only 30 patients (4%). In univariate analysis, there were no differences in age, sex, race/ethnicity, or immunosuppression comparing those who experienced breakthrough or post-prophylaxis CMV DNAemia compared to those without CMV DNAemia, but there were differences based on transplanted organ (p heart > kidney) and CMV risk status (high and intermediate) (p<0.001). Neutropenia (p<0.001) and lymphopenia (p=0.003) as well as VGCV discontinuation or dose reduction for perceived toxicity (p<0.001) were associated with breakthrough CMV infection. Bacteremia (p=0.001), EBV viremia (p=0.02), and adenovirus viremia (p=0.002) were also documented more in those with breakthrough compared to those who never had CMV DNAemia. In an adjusted Cox regression hazard model using all significant univariate variables, transplanted organ, CMV risk status, toxicity related VGCV modification (p=0.005), and bacteremia (p=0.01) were independently associated with breakthrough CMV infection. Breakthrough CMV was also associated with rejection (p=0.01) in a separate logistic multivariable model. Both liver (p<0.001) and heart transplant (p<0.001) patients had a greater risk of rejection over the first year of transplantation, but only liver transplant patients had a greater risk of rejection with breakthrough CMV infection (p=0.004). Post prophylaxis CMV DNAemia was associated with mortality at 1 year in the univariate analysis in the full cohort (p=0.001).ConclusionRates of CMV disease when using valganciclovir prophylaxis were low in this large, multicenter cohort of pediatric SOT recipients. However, breakthrough CMV infection continues to be a problem in intermediate- and high-risk CMV patients and is associated with significant morbidity and rejection, particularly in the liver transplant population. Alternative approaches to prevent breakthrough and post-prophylaxis CMV and with a better safety profile should be studied in pediatric SOT patients.Table 1 Demographic and clinical characteristics of study patients Overall n=749 No DNAemia n=618 Breakthrough CMV n=85 Post-PPX CMV n=46 Overall p-value Breakthrough vs No DNAemia Post-PPX vs No DNAemia Demographics Age, years, median (IQR)8.4 (2.3-13.8)9.0 (2.4-13.7)5.5 (1.4-14.1)7.6 (3.4-12.3)0.20.10.9Sex, female, n (%)339 (45.3)277 (44.8)42 (49.4)20 (43.5)0.70.40.9Race, n (%)0.20.10.4 White264 (67.5)212 (69.3)28 (54.9)24 (70.6) Black53 (13.6)39 (12.8)7 (13.7)7 (20.6) Asian20 (5.1)15 (4.9)4 (7.8)1 (2.9) Other/Declined54 (13.8)40 (13.1)12 (23.5)2 (5.9)Ethnicity, n (%)0.20.70.09 Hispanic193 (26.1)156 (25.6)20 (23.8)17 (37.0) Clinical features Transplanted organ, n (%)<0.001<0.0010.07 Kidney294 (39.3)269 (43.5)14 (16.5)11 (23.9) Liver227 (30.3)169 (27.4)39 (45.9)19 (41.3) Heart169 (22.6)136 (22.0)19 (22.4)14 (30.4) Lung40 (5.3)30 (4.9)9 (10.6)1 (2.2) Other19 (2.5)14 (2.3)4 (4.7)1 (2.2)CMV risk group, n (%)<0.001<0.0010.002 High risk (D+/R-)316 (42.7)245 (40.1)49 (59.0)22 (47.8) Intermediate risk (D+/R+ or D−/R+)291 (39.3)235 (38.5)32 (38.6)24 (52.2) Low risk (D-/R-)133 (18.0)131 (21.4)2 (2. -Abstract Truncated-
pediatrics,infectious diseases